Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 2/20 | 0.47 |
| ▸ | PER2 | O15055 | 3/20 | 0.44 |
| ▸ | CRY2 | Q49AN0 | 3/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 12/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 12/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019427 | 0.81 | PRF1 (0.44) | PRF1TDP2KDM4EALOX15TSHR | |
| SCHEMBL2018210 | 0.78 | PRF1 (0.46) | PRF1TDP2KDM4EALOX15TSHR | |
| SCHEMBL22226933 | 0.74 | ADAM17 (0.37) | PRMT5WDR77TDP2KDM4EALOX15 | |
| SCHEMBL2020810 | 0.73 | PRF1 (0.68) | PRF1PER2CRY2 | |
| SCHEMBL2016656 | 0.69 | GRM5 (0.50) | PRF1 | |
| SCHEMBL7966325 | 0.69 | PER2 (0.42) | PRF1PER2CRY2PRMT5WDR77 | |
| SCHEMBL24439282 | 0.69 | PRF1 (0.36) | PRF1PER2CRY2 | |
| SCHEMBL15795942 | 0.69 | PRMT5 (0.50) | PER2CRY2PRMT5WDR77 | |
| SCHEMBL1441245 | 0.68 | CASP3 (0.43) | PRF1TDP2 | |
| SCHEMBL20678234 | 0.68 | KDM4E (0.38) | KDM4EALOX15TSHRSIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | PRF1 1/4885PER2 4766/4885CRY2 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.